Akkermansia muciniphila

Overview

Akkermansia muciniphila is a gut bacterium that lives in your intestinal mucus layer and eats mucin, the protein that layer is made of, which sounds destructive and is closer to the opposite: it keeps the layer turning over. You almost certainly already host it, at more than one percent of the bacterial cells in your stool. The catch is that the one randomized human trial of it got its results from dead cells, not live ones.

What is Akkermansia muciniphila?

Quick facts

Key Takeaways

• In the only randomized trial of Akkermansia muciniphila on its own (40 enrolled, 32 completers, three months), the pasteurized non-living cells produced every significant result and the live cells produced none.
• The human-studied dose is 10 billion cells a day. US products run from 100 million to 50 billion per serving, and most of them do not tell you which unit they counted.
• CFU, AFU and TFU are three different counts: cells that grow on a plate, live cells counted by flow cytometry, and every cell whether living or dead. A TFU number sitting next to a competitor's CFU number is not a comparison.
• Two larger trials since then missed their primary endpoints, including a 142-adult, four-month trial of 30 billion pasteurized cells a day where the only positive numbers came from subgroups defined after the fact.
• Both larger trials found the effect concentrated in people who started with low levels of their own Akkermansia, which is the reverse of how the ingredient is usually sold.
• You are not deficient in it by default. It colonizes infants within the first year of life at close to adult levels and declines in old age.
• Pasteurized Akkermansia has a 90-day rat toxicology study with no adverse effects at the highest dose tested, plus a 2022 EU novel-food authorization. The longest randomized human exposure on record is four months.

What is Akkermansia muciniphila?

It is a single bacterial species, and an unusual one. Most of the bacteria in a probiotic capsule are lactobacilli and bifidobacteria, which ferment sugars in the lumen of your gut, the open channel where food passes. Akkermansia lives one layer in, inside the mucus that coats your intestinal wall, and its food is that mucus. Specifically it eats mucin, the heavily sugared protein that gives mucus its texture. Give it mucin as the only carbon and nitrogen source and it grows happily, which is exactly how it was first isolated from human stool in 2004 and given a name (Derrien 2004). The type strain is called MucT, a label you will occasionally see on a label.

A bacterium that eats your gut lining sounds like a problem. The counterintuitive part, and the reason anyone cares, is that mucin turnover appears to be how the layer stays healthy, and the species sits at the point where your tissue and your microbes meet. It belongs to Verrucomicrobia, a phylum that is otherwise barely present in the human gut, so it has almost no close relatives in there. Taxonomically it is on its own.

It is also not exotic. A probe-based count found it at more than 1 percent of all fecal bacterial cells in healthy adults, which makes it one of the more abundant single species in the gut (Derrien 2008). Infants pick it up in the first year of life and reach roughly adult levels, around 100 million cells per gram, then levels fall in the elderly (Collado 2007). So the honest framing for a supplement is not "you are missing this bacterium." It is "you may have less of it than someone else, and whether topping it up does anything is the open question."

Why it is hard to put in a capsule

Akkermansia is a strict anaerobe. It was described as one in 2004, and the refinement since then is that it tolerates and even uses oxygen at nanomolar concentrations, the thin band that leaks out of your gut wall, not the air inside a bottle (Ouwerkerk 2016). The published laboratory protocol for keeping viable cells involves glycerol and minus 80 degrees Celsius, which gave about 98 percent survival over a year (Ouwerkerk 2017). That is a freezer, not a pantry. Keeping this organism alive from a fermenter to your kitchen counter is a genuine engineering problem, and it is the single fact that explains most of what you will see on a shelf.

The field solved the problem by giving up on keeping it alive. In 2016 the Louvain group found that pasteurizing the bacterium, a defined heat treatment, did not reduce its effect in mice but increased it (Plovier 2017). That reframed Akkermansia as a candidate postbiotic, which an international expert panel defines as a preparation of inanimate microbes or their components that confers a health benefit (Salminen 2021). Dead, in other words, by design and not by accident. Our own blog has the longer version of why the pasteurized form is the one that ended up in products.

What raises your own levels

Three things move it, none of them a food containing it. Diet composition: in a randomized crossover feeding trial, a typical Australian diet raised mucus-associated A. muciniphila about 19-fold relative to participants' habitual diet, while a low-FODMAP diet reduced total bacterial abundance (Halmos 2015). Polyphenols: cranberry extract raised Akkermansia in mice fed a high-fat, high-sucrose diet, and the polyphenol literature generally points the same way, including for compounds like quercetin (Anhê 2015). And fiber, in the other direction: strip fiber out and the microbiota turns on the mucus layer itself for food, thinning it (Desai 2016). If you want the general picture of how all of this fits together, start with how the gut microbiome actually works.

How it works

Akkermansia does not work the way a vitamin works. There is no receptor it fills and no deficiency it corrects. The proposed mechanism runs through the gut lining, and most of it was worked out in mice and in cell culture.

Start with the mucus layer. It is a two-part gel: a dense inner layer the bacteria normally cannot enter, and a looser outer layer where they live. Akkermansia grazes on the outer layer, and the released sugars feed other bacteria, which is why its presence changes the neighborhood and not just itself. When mice on a high-fat diet were given live A. muciniphila, the mucus layer thickened back toward normal, fat mass gain slowed, and markers of a leaky gut fell. The same study gave heat-killed cells as a control and they did nothing, which is the first half of a story that gets strange (Everard 2013).

The second half: three years later, the same group found that pasteurization, a gentler and defined heat treatment, made the bacterium work better in mice rather than worse. They traced part of the effect to Amuc_1100, an abundant protein on the organism's outer membrane that survives the temperatures used for pasteurization (Plovier 2017). "Dead" turns out not to be one thing. How you kill the cells determines whether the active surface protein is still intact.

Amuc_1100 is the most concrete piece of the mechanism. In human cell culture, that protein and its associated pili bind Toll-like receptor 2 and Toll-like receptor 4, two of the sensors your immune cells use to recognize microbes, and the result is a cytokine pattern dominated by interleukin-10, an anti-inflammatory signal, along with tighter junctions between gut-lining cells measured as higher trans-epithelial resistance (Ottman 2017). So: a surface protein talks to an immune receptor, the immune tone shifts toward tolerance, and the lining holds together better. In a dish.

There is a second proposed route involving gut hormones. A protein the organism secretes, named P9, triggered release of glucagon-like peptide-1 (GLP-1, the gut hormone that signals fullness and prompts insulin release) and raised brown-fat thermogenesis in mice, apparently by binding intercellular adhesion molecule 2 (Yoon 2021). This one is proposed, not proven in people. The human signal that would support it is a larger GLP-1 excursion after a glucose load in the 142-person trial, and that was an exploratory analysis rather than the endpoint the trial was built to test (Suenaert 2026).

One more mechanistic wrinkle worth knowing, because it predicts who responds. Metformin raises Akkermansia. It did so in high-fat-fed mice, where the increase tracked with better glucose tolerance (Shin 2014), and people taking metformin carry more of it than matched people who are not (de la Cuesta-Zuluaga 2017). Two reviews from the groups that did most of this work lay out the full case, including the places it is still correlation (Cani and de Vos 2017, Cani 2022).

All of which sets up the outcomes below. A thicker mucus layer and a calmer immune tone in the gut wall are the proposed upstream events. Barrier markers, insulin sensitivity, GLP-1 and body weight are the downstream outcomes people have actually tried to measure in humans, and they do not all grade the same.

Evidence at a glance

What the evidence doesn't support yet

Weight loss. This is the claim doing the most commercial work and it has never reached significance. In the original trial, body weight finished 2.3 kg below placebo at p = 0.09, which the authors reported honestly as a slight decrease. In the 58-person trial of live cells, both groups lost weight and the difference between them was not significant. A number that misses in the smallest, friendliest trial and then misses again does not become true through repetition.

"Live is the premium version." The pasteurized arm is the one that produced the significant results in the only trial that ran both, and pasteurization improved the effect in mice. A brand charging more for live cells is charging for the harder manufacturing problem, not for better evidence.

"It rebuilds your gut lining." In humans, barrier measures have only ever been secondary endpoints. The thickened mucus layer everyone cites is from mice, and the tighter cell junctions are from a dish. That may well translate. It has not been shown to.

"Everyone is low and everyone benefits." The two larger trials both found the improvements concentrated in participants who started with low levels of their own Akkermansia, and the live-cell trial found poor colonization in people who already had plenty. Combined with the fact that it is already more than 1 percent of a typical adult's gut bacteria, the sensible read is that this ingredient has a target population and most people do not know whether they are in it.

Clinical evidence

• Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study — Forty overweight or obese insulin-resistant adults at a single center in Belgium, 32 of whom completed; three months; 10 billion A. muciniphila cells daily, either live or pasteurized, against placebo; primary endpoints safety, tolerability and metabolic parameters. Pasteurized cells improved insulin sensitivity by 28.6 percent (p = 0.002), cut fasting insulin by 34.1 percent (p = 0.006) and lowered total cholesterol by 8.7 percent (p = 0.02); body weight finished 2.3 kg below placebo but missed significance (p = 0.091); the live arm did not produce the same significant changes and the overall gut microbiome structure was unchanged. The limitation that matters: 32 people at one site for three months, all with existing insulin resistance, which says nothing about healthy adults.
• Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels — 142 adults with metabolic syndrome, with or without prediabetes, across sites in Ireland and Germany; four months; capsules of 30 billion pasteurized A. muciniphila MucT cells daily against placebo; primary endpoint whole-body insulin sensitivity by Matsuda index. The primary endpoint did not differ from placebo in the intention-to-treat analysis. Exploratory analyses at three months found 12 percent better HOMA-based hepatic insulin sensitivity in the prediabetic subgroup (p = 0.05) and in those 63 and older, a larger post-glucose-load GLP-1 excursion (p < 0.01), and in participants with low baseline Akkermansia gene counts, improved insulin sensitivity, decreased trunk fat (p < 0.05) and a borderline weight reduction (p = 0.06). The limitation: the headline result is a null, and every positive number here comes from a subgroup analysis specified after the fact. Four of the authors work for the company selling the ingredient.
• Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: efficacy depends on its baseline levels in the gut — 58 adults with overweight or obesity and type 2 diabetes in Shanghai; 12 weeks; live A. muciniphila (strain AKK-WST01) or placebo on top of routine lifestyle guidance. Both groups lost weight and lowered HbA1c with no significant difference between them. In participants who started with low Akkermansia, the live strain colonized well and body weight, fat mass and HbA1c all fell, changes absent in placebo; in participants who already carried high levels, it colonized poorly and did nothing measurable. The pattern was reproduced in germ-free mice given high- or low-Akkermansia human stool. The limitation: the overall trial is a null result, and the responder finding is a subgroup analysis in 58 people.
• Pasteurized Akkermansia muciniphila HB05 (HB05P) improves muscle strength and function: a 12-week, randomized, double-blind, placebo-controlled clinical trial — 100 adults aged 60 and over in South Korea; 12 weeks; a fixed daily oral dose of pasteurized A. muciniphila HB05 against placebo. Peak torque and peak torque per body weight in the left leg extensors improved over placebo (p = 0.010 and p = 0.005) and follistatin, which opposes the muscle-restraining protein myostatin, rose (p = 0.006); no safety concerns separated the groups. The limitations are substantial: a single trial, run by the company that owns the strain, with the strength benefit appearing in the left leg and not the right, which is not how a systemic effect usually presents.
• Improvements to postprandial glucose control in subjects with type 2 diabetes: a multicenter, double blind, randomized placebo-controlled trial of a novel probiotic formulation — 76 adults with type 2 diabetes; 12 weeks; twice-daily capsules of a three-strain (WBF-010) or five-strain (WBF-011) live anaerobe formulation containing A. muciniphila plus inulin, against placebo. The five-strain product improved the primary endpoint, glucose total area under the curve, by 36.1 mg/dL/180 min (p = 0.0500), with HbA1c down 0.6 and incremental AUC down 28.6 mg/dL/180 min; no safety or tolerability problems appeared. The limitation that matters for this page: Akkermansia was one of five strains plus a prebiotic fiber, so nothing here attributes the effect to Akkermansia, and the p value on the primary endpoint sits exactly at the threshold.
• Diets that differ in their FODMAP content alter the colonic luminal microenvironment — 27 people with irritable bowel syndrome and 6 healthy controls; two 21-day provided diets in randomized crossover with a washout, differing only in fermentable carbohydrate content (3.05 vs 23.7 g/day); stool pH, short-chain fatty acids and bacterial abundance measured. Relative to participants' habitual diet, the typical Australian diet raised mucus-associated A. muciniphila by a median factor of 19.3 (p < 0.001), while the low-FODMAP diet raised stool pH and reduced total bacterial abundance. The limitation: this measures the bacterium, not any health outcome tied to it, and the subjects were mostly people with IBS.
• Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology — 49 overweight and obese adults, 41 of them women; six weeks of calorie restriction followed by six weeks of weight stabilization; stool A. muciniphila, microbial gene richness and clinical measures taken before and after. Higher baseline A. muciniphila went with lower fasting glucose, smaller waist-to-hip ratio and smaller subcutaneous adipocytes, and those participants improved more in insulin-sensitivity markers after calorie restriction. The limitation: this is an association inside a diet study, so it cannot say whether the bacterium caused the better outcome or simply marked a healthier gut to begin with.
• Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut — 112 community-dwelling Colombian adults: 28 with type 2 diabetes (14 taking metformin) and 84 without, matched 3-to-1 on sex, age and BMI; single time point; 16S rRNA sequencing of stool. Participants with diabetes who took metformin had higher relative abundance of A. muciniphila and of several short-chain-fatty-acid producers than participants without diabetes, while those with diabetes not taking metformin did not. The limitation: cross-sectional with 14 people in the metformin group, so it establishes a correlation and no direction of causation.
• High-level colonisation of the human gut by Verrucomicrobia following broad-spectrum antibiotic treatment — Two hospitalized adults, one with a vascular infection and one in intensive care, after broad-spectrum antibiotic regimens; single stool sample each, examined by Gram stain, electron microscopy, 16S pyrosequencing and fluorescence in situ hybridization. Verrucomicrobia made up 44.9 and 84.6 percent of sequences, all of it A. muciniphila, with no notable gastrointestinal symptoms in either patient; the type strain tested susceptible to imipenem and doxycycline and resistant to vancomycin and metronidazole. The limitation: two case reports, which show that antibiotics can upend this population without telling you what the bloom means.
• The mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract — Healthy adult stool samples; single time point; a purpose-built 16S rRNA probe (MUC-1437) validated and read by fluorescence in situ hybridization to count cells directly rather than amplify DNA. A. muciniphila accounted for more than 1 percent of total fecal cells, establishing it as a common and abundant member of the normal human gut rather than a rarity. The limitation: a small descriptive survey from one laboratory, which fixes the order of magnitude and not the normal range.
• Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly — Stool from infants, adults and elderly subjects; cross-sectional; fluorescence in situ hybridization plus real-time PCR against the A. muciniphila 16S rRNA gene. Colonization begins in early life and reaches close to adult levels, around 100 million cells per gram, within the first year, then falls significantly in the elderly (p < 0.05). The limitation: group sizes are small and this is a snapshot rather than a cohort followed over time, so the age decline is an inference across groups.
• Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity — C57BL/6 mice on a high-fat diet; daily oral A. muciniphila, live or heat-killed, against vehicle. Live cells reversed fat-mass gain, metabolic endotoxemia, adipose inflammation and insulin resistance, restored mucus-layer thickness and raised intestinal endocannabinoids; heat-killed cells did none of it. The limitation, and it is the whole limitation of this field: mice, on a diet no human eats, with the causal demonstration resting on a species whose behavior in the human gut is different.
• A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice — Obese and diabetic mice; A. muciniphila grown on a synthetic human-compatible medium, given live or pasteurized, plus the isolated outer-membrane protein Amuc_1100. Pasteurization increased rather than reduced the effect on fat mass, insulin resistance and dyslipidemia; Amuc_1100 proved stable at pasteurization temperatures, interacted with Toll-like receptor 2, improved the gut barrier and reproduced part of the whole-organism benefit. The limitation: the efficacy data are entirely in mice, and the paper's human component tested only that live and pasteurized cells were safe to administer.
• Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice — High-fat-diet C57BL/6J mice plus intestinal L cells in culture; purified P9, an 84 kDa protein secreted by A. muciniphila, identified by chromatography and mass spectrometry. P9 alone raised GLP-1 secretion and brown-adipose thermogenesis through uncoupling protein 1, acting via intercellular adhesion molecule 2, and the effect disappeared without interleukin-6. The limitation: a clean mechanism in mice and cells with no human counterpart yet, which is why the GLP-1 finding in the 142-person trial is described as exploratory rather than confirmatory.
• A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility — Germ-free mice colonized with a synthetic 14-species human gut community including A. muciniphila; chronic or intermittent fiber-free diets against a fiber-containing diet; mucus thickness, microbial gene expression and susceptibility to the pathogen Citrobacter rodentium measured. Without dietary fiber the community switched to eating host mucus glycoproteins, eroding the colonic mucus barrier and allowing lethal colitis from a pathogen the fiber-fed mice survived. The limitation: a defined 14-species community in gnotobiotic mice, which is a model of a gut rather than a gut, though the mechanism is the clearest demonstration available of why fiber intake and this bacterium are connected.
• Toxicological safety evaluation of pasteurized Akkermansia muciniphila — Han Wistar rats, both sexes; 90 consecutive days of oral gavage with pasteurized A. muciniphila at 75, 375 or 1,500 mg/kg body weight per day against vehicle, plus two in vitro genotoxicity assays; clinical observations, body weight, food and water intake, clinical pathology, organ weights and histopathology assessed. Both genotoxicity tests were negative and no test-item-related adverse effects appeared at any dose, so the highest dose tested, 1,500 mg/kg/day, was set as the no-observed-adverse-effect level. The limitation: a 90-day rodent study funded by the ingredient's developer, which is the standard package for a novel food and is not the same as long-term human safety data.
• Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium — Human feces diluted to extinction in anaerobic medium with gastric mucin as the only carbon and nitrogen source; strain MucT isolated in pure culture by the anaerobic soft-agar technique and characterized. The organism is a Gram-negative, strictly anaerobic, non-motile, non-spore-forming oval bacterium that grows best on mucin, grows poorly on a few simple sugars only when protein is also present, and by 16S rRNA sequence belongs to Verrucomicrobia with its closest described relative only 92 percent similar, warranting a new genus. The limitation: a taxonomic description, which tells you what the organism is and nothing about what it does to a person.
• Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function — Human cell lines and cultured immune cells; purified Amuc_1100, an abundant outer-membrane pili-like protein from A. muciniphila MucT, and enrichments containing its associated proteins. The protein activated Toll-like receptor 2 and Toll-like receptor 4 and drove a cytokine profile dominated by interleukin-10, comparable to that produced by recognized immune-calming species, and raised trans-epithelial resistance, a laboratory measure of how tightly a cell layer holds together. The limitation: cell culture, so the barrier result is a dish of cells rather than an intestine, and nothing in it establishes a dose a person would take.

Dosage & forms

• Pasteurized Akkermansia muciniphila (whole cells, heat-treated to a defined specification):
• Live Akkermansia muciniphila:
• Loosely labelled postbiotic Akkermansia preparations:
• Multi-strain blends that include Akkermansia:

Safety & interactions

How much to take

Ten billion cells a day, if you are matching the human research. That is the dose in the only randomized trial of Akkermansia muciniphila on its own, given as pasteurized cells for three months (Depommier 2019). The larger four-month trial tripled it to 30 billion pasteurized cells a day and missed its primary endpoint, so there is no evidence that more is better, and the 12-week muscle trial in adults over 60 used a pasteurized dose in the same general range as the original (Kang 2024).

What products actually carry is another matter. Across the five sold in the US that we checked in October 2026, servings ranged from 100 million cells to 50 billion, a 500-fold spread, which means the label number alone tells you very little. Half of them do not match the studied dose in either direction. Our own capsule carries 5 billion TFU, which is half the studied amount, and we would rather say that plainly here than let you find out by doing the arithmetic.

Timing is simple because nothing about this ingredient is absorption-dependent. The trials dosed daily; the usual label instruction is with a meal; there is no fat requirement and no evidence favoring morning over evening. Take it with whichever meal you will remember.

Expect nothing quickly. The trials measured their outcomes at three and four months, and the outcomes they measured were blood markers rather than sensations. There is no symptom that tracks this organism in a way you would notice in a week, which also means there is no feedback signal telling you it is working. If you try it, give it the three to four months the research used and judge it on whatever your clinician is already measuring.

There is a stated ceiling. The European Food Safety Authority concluded that 34 billion cells a day is safe for adults, excluding pregnant and breastfeeding women, by applying a 200-fold uncertainty factor to the no-effect level from the 90-day rat study (EFSA 2021). At least one product sold in the US sits above that ceiling. More is not better here, and above 34 billion you are outside the only number any regulator has put on paper.

Safety profile

The strongest safety data in humans is also the thinnest part of this page, so here is the full extent of it. The original trial reported daily dosing of 10 billion live or pasteurized cells as safe and well tolerated over three months in 32 completers, with safety as a primary endpoint (Depommier 2019). The blend trial in 76 adults reported no safety or tolerability problems over 12 weeks (Perraudeau 2020). The muscle trial in 100 older adults found no safety concerns separating the groups over 12 weeks. The longest randomized exposure on record is four months at 30 billion cells a day in 142 adults (Suenaert 2026). Add it up and a few hundred people have taken this under observation, for no longer than four months.

Preclinically the package is more complete. Rats given pasteurized cells by gavage for 90 days showed no adverse effects at any dose, including the highest tested, and two genotoxicity assays came back negative (Druart 2021). On that basis EFSA concluded the pasteurized ingredient is safe at 34 billion cells a day, and the European Commission authorised it as a novel food in Implementing Regulation (EU) 2022/168, in force 1 March 2022, with a condition worth noting: the viable cell count has to be below the limit of detection, meaning the authorised ingredient is specifically the non-living one.

Side effects by frequency is a table we cannot honestly build. None of the published trials reports a distinctive side-effect pattern for Akkermansia, and none breaks adverse events out by frequency for the Akkermansia arm specifically. With a few hundred people randomized in total, uncommon effects would not have shown up yet. The gas or bloating people sometimes report on a blend is more plausibly the prebiotic fiber or the conventional cultures than the Akkermansia component.

Interactions

Who should ask a clinician first

Pregnancy and breastfeeding, because EFSA's safety conclusion explicitly excludes both groups and no trial has enrolled them. Anyone taking medication that suppresses the immune system. Anyone currently hospitalized, seriously ill, or with a central venous catheter. Anyone in cancer treatment, particularly on immunotherapy. Children and teenagers, because every trial described on this page enrolled adults and several enrolled only adults in a narrow age band. And anyone whose clinician is actively managing their gut, who should hear about it before you start rather than after.

Signs of taking too much are not something the literature describes, which is worth stating rather than implying: no human overdose pattern has been published, and the 34 billion cell ceiling is a regulatory conclusion drawn from rodent data, not a threshold anyone has crossed and documented in people. The cautious reader's one sentence: this is a well-tolerated ingredient on four months of human data with a modest and inconsistent benefit, so there is no reason to take it urgently and no reason to take more than the trials used.

Buying guide

Does the dose match the one human trial

Ten billion cells a day is the benchmark, because that is what the only randomized trial of the ingredient on its own used. Hold a label against it. Five billion is half the studied dose; 500 million is five percent of it; 50 billion is five times it and sits above the only regulatory ceiling anyone has published. Products at every one of those points are on sale right now, which is why the number on the front of the bottle is where buying this starts.

Check which unit was counted

Three units are in circulation and they measure different things. CFU counts cells that grow into colonies on a plate. AFU counts live cells with intact membranes by flow cytometry, which catches cells a plate would miss. TFU counts every cell the cytometer sees, living or dead, which is the right unit for something non-living and the wrong unit to compare against anyone's CFU. A label that gives a big number without naming the unit has told you nothing, and a blend that adds a TFU figure to a CFU figure for one impressive total has told you something worse.

Live or pasteurized, stated on the label

The form should be printed, not inferred. If a product claims live cells, it should also tell you how to store it, since viability is the whole value proposition and this organism is difficult to keep alive. A live claim with no storage instruction is the gap to ask about. If a product is non-living, the useful disclosures are the strain and how the cells were inactivated, because defined pasteurization and crude heat-killing did not behave the same way in the animal work.

Testing you can actually see

Ask for the certificate of analysis for the lot in your hand, and ask what was tested: identity, count at the stated unit, and contaminants. Here is our own stack, stated as fact. 3-in-1 Probiotic Fusion is made in our own cGMP facility in Mt. Angel, Oregon, every batch is tested in our in-house lab for identity, potency and purity, and a certificate of analysis is published by lot (how we test, and what the documents mean). What you should demand from any brand, including ours: a lot-specific document, not a generic quality page, and a count guaranteed through the expiration date rather than at manufacture. If you want the general version of how to read these claims, our guide to supplement testing and quality covers it.

Price per day, not price per bottle

Divide the price by the servings before comparing anything. In our October 2026 check the five products on the market ran from about 83 cents to about $2.33 a day, which is a three-fold range that bottle prices hide completely. 3-in-1 Probiotic Fusion is $41.99 for 30 capsules at one capsule a day, so $1.40 a day, and it puts a prebiotic, 13 live cultures and the Akkermansia postbiotic in a single capsule to support digestive balance and a healthy gut lining.† For the full side-by-side with every brand's math shown, see our Akkermansia buying guide, and if you are weighing a well-marketed alternative, we also put ours head to head with Seed DS-01.

Red flags

A proprietary blend that hides the Akkermansia amount. "Clinically proven" with no study named, when there is exactly one trial of the ingredient alone and it is easy to cite. A live claim with no strain code and no storage instruction. Any brand implying you are deficient in a bacterium that already makes up more than one percent of a typical adult's gut flora. And a slimming or weight-loss claim, since that number has never reached statistical significance in any human trial of this organism.

Frequently Asked Questions

What is Akkermansia and why is it different from other probiotics?

Akkermansia muciniphila is a gut bacterium that lives in the mucus layer lining your intestine and feeds on mucin, the protein that layer is built from. Conventional probiotics are mostly lactobacilli and bifidobacteria, which live in the open channel of the gut and ferment sugars. Two other differences matter commercially. Akkermansia is a strict anaerobe that is difficult to keep alive outside the gut, and the version with a positive human trial behind it is not alive at all: it is pasteurized cells, sold as a postbiotic.

What does the human evidence actually show?

One small randomized trial and two larger ones that missed their primary endpoints. In the first (40 enrolled, 32 completers, three months), 10 billion pasteurized cells a day improved insulin sensitivity about 29 percent against placebo. A 142-adult, four-month trial of 30 billion cells a day found no difference in whole-body insulin sensitivity, with positive numbers only in subgroups. A 58-person trial of live cells found no overall difference either. Both larger trials found benefit concentrated in people who started with low levels of their own Akkermansia. The honest summary: one small positive trial, mostly mouse work underneath it.

Live vs pasteurized Akkermansia: which was studied?

Both, in the same trial, and pasteurized won. The 2019 Nature Medicine study randomized participants to live cells, pasteurized cells or placebo; the pasteurized arm produced the significant improvements and the live arm did not. That result was predicted by mouse work in which pasteurizing the bacterium increased its effect rather than reducing it, with credit given to a heat-stable outer-membrane protein called Amuc_1100. A separate 2025 trial of a live strain found benefit only in people who started with low levels. Paying extra for live cells buys a harder manufacturing problem, not better evidence.

What dose (AFU or CFU) did the trials use?

Ten billion cells a day for three months in the original trial, and 30 billion a day for four months in the larger one. Both counted cells of a pasteurized, non-living preparation, so neither CFU nor AFU applies: those units measure viability, and viability was not the point. Products in the US range from 100 million to 50 billion per serving, a 500-fold spread, and they use CFU, AFU and TFU inconsistently. TFU counts every cell whether living or dead, which is the right unit for a postbiotic and not comparable to a CFU figure.

Does Akkermansia survive stomach acid, and does it need refrigeration?

Both questions come down to whether the cells are alive. For a pasteurized or postbiotic preparation neither applies: acid cannot kill what is not alive, and there is no viability to lose, which is why those products are typically shelf-stable and why our own label gives no refrigeration instruction. Whether acid degrades the active surface protein on the way through has not been measured in people, and that is a real gap. For live products both questions are legitimate and unanswered. No published human study measures how many cells survive the stomach, the organism is a strict anaerobe that tolerates oxygen only at nanomolar levels, and the published protocol for preserving viable cells uses glycerol at minus 80 degrees Celsius. A live claim should therefore arrive with a storage instruction; if it does not, that is the question to put to the brand.

Can you raise Akkermansia with food instead?

You can move it with diet, though no food contains it. In a randomized crossover feeding trial, a typical Australian diet raised mucus-associated A. muciniphila about 19-fold relative to participants' habitual diet, while a low-FODMAP diet lowered overall bacterial abundance. Polyphenol-rich extracts such as cranberry raised it in mice. Fiber deprivation pushes the opposite way: in gnotobiotic mice, a fiber-free diet made the microbiota eat the mucus layer itself. What nobody has shown is that raising it through food produces the outcomes the supplement trials were chasing.

Is Akkermansia safe long term?

Unknown, and that is the accurate answer rather than a cautious one. The longest randomized human exposure on record is four months, at 30 billion pasteurized cells a day in 142 adults. Across every published trial, a few hundred people have taken it under observation and none of them for longer than that. The preclinical package is more complete: a 90-day rat study found no adverse effects at the highest dose tested, two genotoxicity tests were negative, and EFSA concluded 34 billion cells a day is safe for adults. Long-term means beyond four months, and beyond four months there is no data.

Who should not take Akkermansia?

Ask a clinician first if you are pregnant or breastfeeding, since EFSA's safety conclusion explicitly excludes both groups and no trial has enrolled them. The same goes for anyone taking immune-suppressing medication, anyone hospitalized or seriously ill, anyone with a central venous catheter, and anyone in cancer treatment, particularly on immunotherapy, where gut bacteria appear to interact with how well the treatment works. Children and teenagers have no trial data at all. If you are on an antibiotic course, finish it, and separate a live product from oral doses by a few hours.

What should an Akkermansia label show?

Five things. The amount per serving, which you should hold against the 10 billion cells used in the human trial. The unit, named explicitly, since CFU, AFU and TFU measure different things and should never be added together. Whether the cells are live or non-living, printed rather than implied. The strain, and for a non-living product how it was inactivated, because defined pasteurization and crude heat-killing behaved differently in animal studies. And a lot-specific certificate of analysis, with the count guaranteed through the expiration date rather than at manufacture.

Do I need this at all?

Probably not, and the research is unusually clear about why. Akkermansia already makes up more than one percent of the bacterial cells in a typical adult's stool, it colonizes infants within the first year of life, and no one has established a deficiency threshold. Both larger trials found the benefit concentrated in participants who started with low levels, and the live-cell trial found poor colonization in people who already had plenty. So the population this ingredient has shown anything in is people with low baseline levels, which almost nobody has measured. If you want a daily probiotic for general digestive support, a [conventional multi-strain product](/blog/digestive/good-flora-probiotic) is the better-evidenced starting point.

Related Mt. Angel Vitamins Products

• Recommended for Akkermansia muciniphila

  3-in-1 Probiotic Fusion – Pre, Pro & Postbiotic Gut Support | 30 or 60 Capsules

  $41.99

  Shop Now